HAE
In the past, few treatment options were available; however, several new therapies with proven efficacy have recently become available to treat and prevent HAE attacks, such as plasma-derived and recombinant C1-INHs that replace the deficient protein, bradykinin receptor antagonist (icatibant) that blocks bradykinin activity and kallikrein inhibitor (ecallantide) that prevents bradykinin release.
In the past, few treatment options were available; however, several new therapies with proven efficacy have recently become available to treat and prevent <span class="disease" id="23634741-4-155-158">HAE</span> attacks, such as plasma-derived and recombinant <span class="gene" id="23634741-4-207-213">C1-INH</span>s that replace the deficient protein, bradykinin receptor antagonist (icatibant) that blocks bradykinin activity and kallikrein inhibitor (ecallantide) that prevents bradykinin release.